• PA
    PA School SurvivalDidactic Year
Study
  • Dashboard
  • Medical Terminology
  • Flashcards
  • Progress
  • Prep Rounds
  • Body Systems
  • Pharmacology
  • Tools
  • Guide & FAQ
  • Suggest a FeatureLet us know what we can do better — we genuinely want to help you in class.
My material
  • My Library
  • Notes & Sketches
PANCE Body Systems
  • Cardiovascular
    11%
  • Pulmonary
    9%
  • Gastrointestinal/Nutrition
    8%
  • Musculoskeletal
    8%
  • Neurology
    7%
  • Infectious Disease
    7%
  • Psychiatry/Behavioral
    7%
  • Reproductive
    7%
  • Endocrine
    6%
  • Eyes/Ears/Nose/Throat
    6%
  • Hematology
    5%
  • Renal
    5%
  • Genitourinary
    4%
  • Dermatology
    4%
Weights are study aids — verify each exam cycle.
⌘K
NotesPricingSign in
About·Tools·Terminology·Privacy Policy·Terms of Service·PANCE Blueprint

PANCE® is a registered trademark of the National Commission on Certification of Physician Assistants (NCCPA). This application is an independent study resource and is not affiliated with, sponsored by, or endorsed by the NCCPA.

For educational use only. Content is AI-generated, may contain errors, and is not medical advice — always verify against current primary sources and faculty guidance before clinical use.

HomePharmacologyDolutegravir

Dolutegravir

Integrase Strand Transfer Inhibitor (INSTI)
Drug Class
Integrase Strand Transfer Inhibitor (INSTI)
Mechanism of Action (MOA)
Inhibits HIV integrase → blocks integration of viral DNA into the host genome.
Clinical Notes
Backbone of first-line ART (usually with two NRTIs) — high resistance barrier, once daily. Weight gain; modest creatinine rise (↓ tubular secretion, not true renal injury); periconception neural-tube-defect signal now considered low risk.
Source
FDA label (DailyMed)
All pharmacology